These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 21653597)

  • 1. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
    Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
    Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
    Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
    Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
    Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
    Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.
    Huang Y; Vasilatos SN; Boric L; Shaw PG; Davidson NE
    Breast Cancer Res Treat; 2012 Feb; 131(3):777-89. PubMed ID: 21452019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.
    Nalawansha DA; Pflum MK
    ACS Chem Biol; 2017 Jan; 12(1):254-264. PubMed ID: 27977115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
    Asklund T; Kvarnbrink S; Holmlund C; Wibom C; Bergenheim T; Henriksson R; Hedman H
    Anticancer Res; 2012 Jul; 32(7):2407-13. PubMed ID: 22753697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.
    El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H
    Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
    Haydn T; Metzger E; Schuele R; Fulda S
    Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
    Reddy RG; Bhat UA; Chakravarty S; Kumar A
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy.
    Mitra R; Ayyannan SR
    Anticancer Agents Med Chem; 2022; 22(18):3062-3085. PubMed ID: 35593350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
    Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
    Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic regulation of Atrophin1 by lysine-specific demethylase 1 is required for cortical progenitor maintenance.
    Zhang F; Xu D; Yuan L; Sun Y; Xu Z
    Nat Commun; 2014 Dec; 5():5815. PubMed ID: 25519973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
    Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
    Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.
    Booth L; Roberts JL; Conley A; Cruickshanks N; Ridder T; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 Mar; 15(3):305-16. PubMed ID: 24351423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soft drug inhibitors for the epigenetic targets lysine-specific demethylase 1 and histone deacetylases.
    Seitz J; Auth M; Prinz T; Hau M; Tzortzoglou P; Schulz-Fincke J; Schmidtkunz K; Baniahmad AA; Willmann D; Metzger E; Hein L; Preissl S; Schüle R; Jung M
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400450. PubMed ID: 39004853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.